Shares of Celgene Corp. tanked on Thursday following the company's release of third-quarter financials, which included a slow growth for arthritis/psoriasis drug Otezla (apremilast) and lowered long-term targets. Meanwhile, Amgen Inc. reported $67 million in pre-tax expenses due to Hurricane Maria's toll on the company's Puerto Rico-based manufacturing facility. It also dropped development of its oral cholesterol ester transfer protein (CETP) inhibitor, resulting in a $116 million charge.